Crizanlizumab-tmca Injection

Crizanlizumab-tmca injection is used to reduce the number of pain crises (sudden, severe pain that may last several hours to several days) in adults and children 16 years of age and older with sickle cell disease (an inherited blood disease). Crizanlizumab-tmca is in a class of medications called monoclonal antibodies. It works by blocking certain blood cells from interacting.

🔔 How should this medicine be used?

Crizanlizumab-tmca injection as a solution (liquid) to be injected intravenously (into a vein) by a doctor or nurse over a period of 30 minutes. It is usually given once every 2 weeks for the first two doses and then once every 4 weeks.

Crizanlizumab-tmca injection can cause serious infusion reactions, which may occur within 24 hours of receiving a dose. A doctor or nurse will watch you closely while you are receiving the infusion and after the infusion to be sure you are not having a serious reaction to the medication. If you experience any of the following symptoms, tell your doctor or nurse immediately: fever, chills, nausea, vomiting, tiredness, dizziness, sweating, rash, hives, itching, wheezing, or difficulty breathing.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.